Nautilus Biotechnology announced Baylor College of Medicine as the inaugural customer for its Voyager single‑molecule proteomics platform, marking an early access deployment ahead of commercial launch. Baylor will use the system in an NIH‑funded project to identify aberrant protein isoforms in cancer and to develop computational toolkits linking full‑length proteoform measurements to shotgun proteomics. Nautilus’s platform combines reagents, imaging, ultra‑dense nano‑array flow cells and machine learning to map intact proteoforms at scale. The company recently field‑tested Voyager at the Buck Institute, using it to interrogate tau proteoform diversity; Baylor’s collaboration aims to extend those assays to tumor proteomics and enable isoform‑resolved biomarker discovery. If the technology delivers reproducible, isoform‑level data at throughput and cost compatible with translational workflows, it could reshape proteomics‑driven biomarker discovery and clinical proteogenomics.